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Apoptotic markers in cultured ﬁbroblasts correlate with brain
metabolites and regional brain volume in antipsychotic-naive
ﬁrst-episode schizophrenia and healthy controls
A Batalla1,2,3,4, N Bargalló5,6,7, P Gassó6,8, O Molina9, D Pareto10, S Mas6,7,8, JM Roca1, M Bernardo2,6,7,11, A Lafuente6,7,8 and
E Parellada1,2,6,7,8,11
Cultured ﬁbroblasts from ﬁrst-episode schizophrenia patients (FES) have shown increased susceptibility to apoptosis, which may be
related to glutamate dysfunction and progressive neuroanatomical changes. Here we determine whether apoptotic markers
obtained from cultured ﬁbroblasts in FES and controls correlate with changes in brain glutamate and N-acetylaspartate (NAA) and
regional brain volumes. Eleven antipsychotic-naive FES and seven age- and gender-matched controls underwent 3-Tesla magnetic
resonance imaging scanning. Glutamate plus glutamine (Glx) and NAA levels were measured in the anterior cingulate (AC) and the
left thalamus (LT). Hallmarks of apoptotic susceptibility (caspase-3-baseline activity, phosphatidylserine externalization and
chromatin condensation) were measured in ﬁbroblast cultures obtained from skin biopsies after inducing apoptosis with
staurosporine (STS) at doses of 0.25 and 0.5 μM. Apoptotic biomarkers were correlated to brain metabolites and regional brain
volume. FES and controls showed a negative correlation in the AC between Glx levels and percentages of cells with condensed
chromatin (CC) after both apoptosis inductions (STS 0.5 μM: r=− 0.90; P= 0.001; STS 0.25 μM: r=− 0.73; P= 0.003), and between NAA
and cells with CC (STS 0.5 μM induction r=− 0.76; P= 0.002; STS 0.25 μM r=− 0.62; P= 0.01). In addition, we found a negative
correlation between percentages of cells with CC and regional brain volume in the right supratemporal cortex and post-central
region (STS 0.25 and 0.5 μM; Po0.05 family-wise error corrected (FWEc)). We reveal for the ﬁrst time that peripheral markers of
apoptotic susceptibility may correlate with brain metabolites, Glx and NAA, and regional brain volume in FES and controls, which is
consistent with the neuroprogressive theories around the onset of the schizophrenia illness.
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INTRODUCTION
Dopaminergic abnormalities are the core feature of psychosis;
however, there are several aspects of schizophrenia that do not
appear to be entirely explained by dopamine dysfunction alone.1
Clinical research has suggested that abnormalities in dopaminergic
neurotransmission may be the ﬁnal common pathway to
psychosis,2 and this may be driven by abnormalities in glutama-
tergic transmission.3–5 The glutamatergic hypothesis of schizophre-
nia was proposed in the early 1990s,6 based on pharmacological
studies with N-methyl-D-aspartate receptor blockers, such as
phencycline and ketamine, which produce psychotomimetic effects
in healthy volunteers and exacerbate symptoms and cognitive
defects in schizophrenia patients.7,8 Normal glutamate (Glu) and
N-methyl-D-aspartate receptor function has a critical role in
synaptogenesis during early development and synaptic elimination
during adolescence.9 The administration of N-methyl-D-aspartate
receptor antagonists to experimental animals during early postnatal
development results in cortical apoptosis, and behavioral, structural
and neurochemical abnormalities associated with schizophrenia.10–12
Deﬁcits in glutamatergic neurotransmission, including NMDA
receptor hypofunction and Glu-induced excitotoxicity, are capable
of activating apoptosis in neurons, which may lead to neuronal
damage and the onset of psychosis in early adulthood.13,14
First-episode schizophrenia patients may have a genetically
increased susceptibility to apoptosis or be more vulnerable to pro-
apoptotic stimuli, such as Glu excitotoxicity, oxidative stress,
reduced neurotrophic support and inter alia.13,15 This increased
apoptosis might explain certain features of schizophrenia, such as
the progressive gray matter (GM) loss identiﬁed in ﬁrst-episode
schizophrenia (FES), or the functional brain deﬁcits observed in
the course of the disease.16,17 Post-mortem studies do not show
clear evidence of decreased cell viability, but local synaptic
apoptosis may reduce neuropil without inducing neuronal
death.18 Reduced dendritic spines, presynaptic marker proteins
and expression of synaptic genes13,19 are consistent with the
hypothesis of loss of neuropil or altered apoptosis.13,15,20
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In vivo measures of glutamate metabolism and neural integrity
may help to test glutamatergic models of schizophrenia and its
relation to apoptotic markers.21 Few studies have examined the
levels of Glu, its metabolite glutamine (Gln) or its combination
(Glx), as well as N-acetylaspartate (NAA), a marker of neuronal
integrity, using proton magnetic resonance spectroscopy
(1H-MRS) in ﬁrst-episode psychosis before treatment.7,22,23 Two
1H-MRS studies in unmedicated ﬁrst-episode patients found
increased Gln/Glu ratio7 and Gln levels23 in the anterior cingulate
(AC), and another in the medial prefrontal cortex.22 Increased Gln
has also been reported in the thalamus in one study,23 as well as
decreased NAA in the AC.7 Studies involving clinical high-risk
populations have also described high levels of Gln in cortical
regions,24,25 although lower26 and negative results have also been
reported.27,28 Importantly, the loss of thalamic Gln in patients with
schizophrenia29 and Glu in subjects at risk of developing
schizophrenia24 has been correlated with GM loss in several brain
regions.
On the basis of evidence that glutamatergic dysfunction may
lead to cortical apoptosis, and that the loss of Glu, Gln and NAA
may be related to loss of synaptic neuropil and structural
abnormalities in different stages of psychotic illness, we hypothe-
sized that changes in Glx and NAA measured with 1H-MRS would
correlate with apoptotic markers obtained from cultured ﬁbro-
blasts in antipsychotic-naive ﬁrst-episode psychotic patients
compared with healthy controls. Several markers enable to detect
morphological, biochemical and molecular alterations in cells
undergoing apoptosis. One of the earliest markers of this
programmed cell death involves the externalization of phos-
phatidylserine residues from the inner to the outer leaﬂet of the
cell membrane.30 Later stages involve the activation of caspases,
caspase-3 being the ultimate and main executor of apoptosis, as
well as chromatin condensation and DNA fragmentation.31,32 We
further hypothesized that apoptotic markers would correlate with
regional brain volume alterations measured with voxel-based
morphometry (VBM), particularly in those areas that may be
expected to be involved in schizophrenia, such as the frontal and
temporal cortex.
MATERIALS AND METHODS
Subjects
Eleven patients (six men and ﬁve women) suffering from a FES and aged
between 19 and 29 years were recruited during acute hospitalization for a
ﬁrst psychotic episode in the inpatient unit of a general academic hospital
(Hospital Clinic, Barcelona) over a period of 2 years. All patients were
antipsychotic-naive at the time of sample collection. Psychopathology and
functionality of patients were assessed with the Positive and Negative
Syndrome Scale (PANSS), the Clinical Global Impression (CGI) and the Global
Assessment of Functioning (GAF) scales. The diagnosis of schizophrenia was
conﬁrmed according to Diagnostic and Statistical Manual of Mental Disorders,
4th Edition, Text Revision after a 2-year follow-up clinical evaluation. Seven
healthy controls (four men and three women), college students from the
University of Barcelona (age range 21–26 years), were also recruited at the
same time. All subjects included in the study were Caucasians, except for one
patient who reported African ancestry. Control subjects were assessed using
a semistructured psychiatric interview (SCID-I), excluding any Axis I psychiatric
disorders. Subjects suffering from mental retardation or from any neurolo-
gical illness were excluded. No subjects suffered from any relevant disease.
Chronic drug treatment was considered a criterion for exclusion. People
meeting Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
criteria for substance abuse or dependence for any substance save nicotine
or cannabis and alcohol used sporadically were also excluded. Demographic
and clinical data are shown in Table 1. After receiving a full explanation of the
study, written informed consent was obtained from each control subject and,
in the case of patients, from their parents. The study was approved by the
Ethics Committee of Hospital Clínic. Two subjects (one patient and one
control) could not ﬁnish the exam and the spectra were not acquired.
Image acquisition and analysis
All images were acquired at a 3 T Siemens Magneto TIM Trio (Siemens
Diagnostics Healthcare, Erlangen, Germany) at the Image Platform of
IDIBAPS, Centre de diagnostic per la Imatge from Hospital Clínic, Barcelona.
We used a 32-channel phased-array head coil with foam padding and
headphones to restrict head motion and suppress scanner noise.
Table 1. Demographic and clinical data of subjects.
Fibroblast cell lines and structural MRI data P-value 1H-MRS P-value
Patients (N=11) Controls (N= 7) Patients (N=10) Controls (N= 6)
Age (mean± s.e.m.) 23.5± 1.1 22.8± 0.9 0.675 23.9± 1.2 22.3± 0.8 0.373
Male gender, N (%) 6 (54.5) 4 (57.1) 0.914 5 (50.0) 3 (50.0) 1.000
Caucasian ethnicity, N (%) 10 (90.9) 7 (100) 0.412 9 (90.0) 6 (100) 0.424
BMI (mean± s.e.m.) 21.3± 1.2 21.4± 0.4 0.913 20.3± 0.7 21.4± 0.4 0.248
Educational levela
Post-compulsory schoolingb, N (%) 9 (81.8) 7 (100) 0.231 8 (80.0) 6 (100) 0.242
University studies, N (%) 1 (9.1) 1 (14.3) 0.732 1 (10.0) 0 (0.0) 0.424
Tobacco use
N (%) 6 (54.5) 2 (28.6) 0.280 5 (50.0) 2 (33.3) 0.515
No. of cigarettes per month 250.9± 81.1 128.6± 89.2 0.327 231.0± 87.0 150.0± 102.5 0.566
Sporadic cannabis use, N (%) 5 (45.5) 3 (42.9) 0.914 4 (40.0) 2 (33.3) 0.790
Sporadic alcohol use, N (%) 9 (81.8) 5 (71.4) 0.605 8 (80.0) 4 (66.7) 0.551
Psychopathology score
PANSS total (mean± s.e.m.) 117.0± 6.2 — — 117.4± 6.9 — —
PANSS positive (mean± s.e.m.) 28.7± 1.3 — — 28.6± 1.4 — —
PANSS negative (mean± s.e.m.) 29.6± 2.3 — — 30.2± 2.5 — —
PANSS general (mean± s.e.m.) 58.7± 4.1 — — 58.7± 4.5 — —
CGI total (mean± s.e.m.) 5.3± 0.3 — — 5.3± 0.3 — —
GAF (mean± s.e.m.) 22± 2.8 — — 21± 3.0 — —
Abbreviations: BMI, body mass index; CGI, clinical global impression; GAF, global assessment of functioning; 1H-MRS, proton magnetic resonance
spectroscopy; MRI, magnetic resonance imaging; PANSS, Positive and Negative Syndrome Scale. aSubjects who completed the corresponding level. bSpanish
baccalaureate or vocational studies.
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1H-MRS acquisition and quantiﬁcation
Single voxel spectra were acquired with the use of a double-spin echo
point-resolved spectroscopy sequence, with repetition time= 1500ms and
echo time= 35ms, data points 2048, with automatic shimming and water
suppression. A volume of interest (VOI) of 12 cm3 was placed in the AC
(30 × 20 × 20mm3), and a second one of 8 cm3 in the left thalamus (LT;
20 × 20× 20mm3). Figure 1 demonstrates representative voxel placement.
This procedure was applied in the same manner in all subjects, and care
was taken to ensure standard placement. For the quantiﬁcation, we used
the user-independent frequency-domain ﬁtting program (LC Model)33,34
version 6.1-4A, using a basis set of model metabolite spectra. Eddy-current
correction was conducted. The unsuppressed water signal was used as an
internal reference, assuming a water concentration of 35 880mmol l− 1 (ref.
35) to estimate the metabolite concentrations. No corrections for
relaxation were performed. Therefore, the concentrations are expressed
as internal units that differ from mmol kg− 1 by factors because of
relaxation, as well as water content in the VOI. Some metabolites are
difﬁcult to quantify independently from others; therefore, the sum of
concentrations was used. The metabolites of the basis set for LC Model
were L-Alanine (Ala), Aspartate (Asp), Cr, gamma-Aminobutyric acid, Glu,
Gln, inositol (mI), L-Lactate (Lac), NAA, N-acetyl aspartateglutamate (NAAG),
Scyllo-Inositol (Scyllo), Taurine (Tau), Glycerophosphocholine (GPCh),
Phosphocholine (PCh), Glycine (Gly), the combined metabolites (GPCh
+PCh, NAA+NAAG and Glu+Gln) and the different groups of lipids and
macromolecules (Lip13a, Lip13b, Lip09, MM09, Lip20, MM20, MM12, MM14
and MM17) and their combinations (Lip13a+Lip13b, MM14+Lip13a+Lip13b
+MM12, MM09+Lip09 and MM20+Lip20). Only the metabolites NAA,
NAAG, Glu, Gln, Cr, GPCh, PCh and mI, some of them combined (GPCh
+PCh referred to as total Cho, NAA+NAAG referred to as total NAA and Glu
+Gln referred to as Glx) were considered as they are the ones that have
been studied the most in the previous schizophrenia literature. A typical
LCM spectrum and ﬁtting for both patients and controls are shown in
Figure 1. We only consider the absolute metabolite values with a Cramer–
Rao lower bound below 20%, indicating that these metabolites could be
reliably estimated,34 and a signal-to-noise ratio greater than 10. We
decided to use the sum Glu and Gln because these metabolites separately
usually do not survive the Cramer–Rao lower bound level.
An additional structural image (3d T1-weighted MPRAGE sequence with
isometric voxel of 1x1x1mm3) was recorded in the same scanning session
(the sequence is described below). Statistical parametric mapping (SPM)
segmentation was performed and cerebrospinal ﬂuid was included in the
VOI (SPM5 software, running in Matlab 6.5, MathWorks, Natick, MA, USA).
Metabolite concentrations were adjusted for the amount of cerebrospinal
ﬂuid in each voxel. The metabolite concentrations were adjusted
for the amount of cerebrospinal ﬂuid contained within the VOI using the
formula: Cmet - corr ¼ CmetVF ´ 100 where VF corresponds to the volume
fraction (percentage of nervous tissue − GM and white matter − contained
in the VOI).36 The 1H-MRS parameters used for the present study provided
robust signals for both the healthy control and FES groups. Speciﬁcally,
healthy controls had an AC and LT signal-to-noise ratio of 68.50 (s.d. = 9.75)
and 15.00 (s.d. = 2.68), respectively, and a full-width at half-maximum of
0.049 p.p.m. (s.d. = 0.013) and 0.079 p.p.m. (s.d. = 0.022), respectively. FES
patients had an AC and LT signal-to-noise ratio of 66.60 (s.d. = 14.58) and
35.90 (s.d. = 55.66), respectively, and a full-width at half-maximum of 0.042
p.p.m. (s.d. = 0.011) and 0.079 p.p.m. (s.d. = 0.016), respectively. None of
these measures was different between the two groups (P40.05), suggesting
that the quality of the data was comparable across the two groups.
Structural volumetric acquisition and VBM analysis
The magnetic resonance imaging protocol included a set of
magnetization-prepared rapid gradient echo T1-weighted images (repeti-
tion time: 2300ms; echo time: 3 ms; ﬂip angle: 15°; ﬁeld of view: 245mm;
and voxel size: 1 × 1 × 1mm3) and axial T2 images (repetition time:
3000ms; echo time: 87ms; ﬂip angle: 120º; ﬁeld of view: 233× 256; and
slice thickening: 3 mm). A neuroradiologist (NB) conﬁrmed that all
magnetic resonance imaging scans were free of gross structural
abnormalities.
The structural MPRAGE images were analyzed with the Statistical
Parametric Mapping software (SPM8; The Wellcome Department of
Imaging Neuroscience, London, UK) following the VBM toolbox (http://
NAA
Glx
NAA
Glx
NAA
Glx
NAA
Glx
Figure 1. Spectroscopic voxel placement in the anterior cingulate (AC) cortex (a) and in the left thalamus (LT; b). Representative spectra of one
control in the AC (c) and in the LT (d) and of one patient in the AC (e) and in the LT (f). Glx, glutamate+glutamine; NAA, N-acetylaspartate.
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dbm.neuro.uni-jena.de/vbm/). Brieﬂy, images were segmented and nor-
malized to the SPM-T1 template using a high-dimensional DARTEL
transformation. In addition, the Jacobian determinants derived from the
spatial normalization were used to modulate image voxel values to restore
volumetric information (afﬁne and nonlinear).37 Finally, images were
smoothed with an 8-mm full-width at half-maximum isotropic Gaussian
kernel.
Differences between patients and controls were assessed for both gray
and white matter portions, as a two-sample t-test. Data were generated at
Po0.001 uncorrected, and only those surviving a cutoff of Po0.05, family-
wise error (FWE) correction at the cluster level for multiple comparisons,
were considered statistically signiﬁcant. Finally, correlations with apoptotic
markers were also analyzed for both gray and white matter VBM, using the
same statistical threshold.
In order to assess whether there was a correlation between the
metabolites (corrected by cerebrospinal ﬂuid factor) and GM concentra-
tion, a multivariate analysis was performed. Total intracranial volume was
included as a covariate. Signiﬁcance level was set at Po0.05 (FWE-
corrected, FWEc).
Fibroblast primary cell culture: markers of apoptotic susceptibility
Hallmarks of apoptotic susceptibility (caspase-3 activity, phosphatidyl-
serine externalization and chromatin condensation (CC)) were measured in
ﬁbroblast cultures obtained from skin biopsies of all subjects after inducing
apoptosis with staurosporine (STS) at doses of 0.25 and 0.5 μM (Sigma-
Aldrich, St Louis, MO, USA). Five markers of apoptotic susceptibility were
considered in the analysis: caspase-3 activity (baseline and 6 h after
treatment with STS 0.50 μM), externalization of phosphatidylserine
(measuring annexin-V 6 h after treatment with STS 0.50 μM) and chromatin
condensation (6 h after STS induction at doses of 0.25 and 0.5 μM). These
biomarkers were chosen on the basis of previous results of increased
apoptotic susceptibility in cultured ﬁbroblasts from antipsychotic-naive FES
patients compared with healthy controls.15 Compared with controls,
cultured ﬁbroblasts from patients showed higher caspase-3 activity and
lower BCL2 expression. When exposed to STS, ﬁbroblasts from patients
also showed higher cleaved caspase-3 activity and protein levels; a higher
percentage of cells with translocated phosphatidylserine and condensed
chromatin (CC); and higher p53 expression.15 The detailed protocol for the
establishment of the skin ﬁbroblast cultures can be found elsewhere.15
Statistical analysis
All statistical analyses were performed using Statistical Package for the
Social Sciences (SPSS, v.19; SPSS, Chicago, IL, USA). Descriptive results are
presented as the mean (s.d.) for continuous variables and frequencies
(absolute and relative) for categorical variables. Group differences in
demographic were explored using Χ2-test, Student’s t-test or Mann–
Whitney U-test, as appropriate. Metabolite measures between groups were
compared using a multivariate regression analysis. The percentages of GM
in the AC and LT were included as covariates. Statistical signiﬁcance was
set at 0.05.
Partial correlations controlling for percentages of GM and for the time of
experiment when the apoptotic hallmarks were measured were conducted
to examine the relationship between apoptotic markers and metabolite
concentrations for each region. The statistical threshold was Bonferroni-
adjusted (P= 0.05/5 = 0.01) to control for multiple comparisons. Statistical
power was calculated according to the recruited sample size. When all
participants were included in the test (n=16), assuming a 5% level of
signiﬁcance, we were able to detect correlation coefﬁcients of r⩾ 0.65 with
⩾ 80% of statistical power; when sample was stratiﬁed according to
diagnosis, we were able to detect r⩾ 0.79 (cases n=10, 5% level of
signiﬁcance and ⩾ 80% statistical power) or r⩾ 0.92 (controls n=6, 5%
level signiﬁcance and ⩾ 80% statistical power).
RESULTS
Cerebral metabolites
There were no signiﬁcant differences between groups in Glx and
NAA levels either in the AC (controls (mean, s.d.): 9.2, 1.1; patients:
7.8, 1.1; F = 4.73, P= 0.149; and controls: 7.3, 1.1; patients: 6.5, 0.8;
F = 1.72, P= 0.339, respectively), or in the LT (controls (mean, s.d.):
5.4, 1.7; patients: 4.8, 1.3; F = 2.08, P= 0.602; and controls: 7.9, 1.0;
patients: 7.5, 0.4; F = 1.21, P= 0.186, respectively). We found no
differences in the other metabolite levels (Inositol, Cr and PCh)
between groups in the AC or LT.
Relationship between apoptotic markers and metabolite levels
Anterior cingulate. There was a negative correlation between Glx
levels and the percentages of cells with CC after both apoptosis
inductions: STS 0.5 μM: r=− 0.90; P= 0.001; STS 0.25 μM: r=− 0.73;
P= 0.003 (Figure 2). When the analysis was performed by group,
we found a negative correlation in the FES group after induction
with STS 0.5 μM (r=− 0.90; P= 0.002) that did not reach corrected
signiﬁcance in controls (STS 0.5 μM: r=− 0.94; P= 0.045). NAA levels
were also negatively correlated with percentages of cells with CC
after induction with STS 0.25 μM (r=− 0.62; P= 0.01) and 0.5 μM
(r=− 0.76; P= 0.002; Figure 2). In the analysis by group, negative
correlations were signiﬁcant in FES after both apoptosis inductions
(STS 0.5 μM: r=− 0.88; P= 0.004; and STS 0.25 μM: r=− 0.89;
P= 0.003) but not in controls (STS 0.5 μM: r=− 0.73; P= 0.266;
and STS 0.25 μM: r=− 0.24; P= 0.747). No further correlations were
found in the AC between Glx or NAA levels and other apoptotic
biomarkers.
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Figure 2. Partial correlation plots showing the association between the residualized values of apoptotic markers and metabolite
concentrations after controlling for percentages of gray matter and for the time of experiement when the apoptotic hallmarks were measured.
(a) Inverse correlation between anterior cingulate Glx (glutamate+glutamine) levels and chromatin condensation (CC) after apoptosis
induction with staurosporine (STS) 0.5 μM in ﬁrst-episode schizophrenia and controls (r=− 0.90; P= 0.001). (b) Inverse correlation between
anterior cingulate N-acetylaspartate (NAA) levels and CC after apoptosis induction with STS 0.5 μM in ﬁrst-episode schizophrenia and controls
(r=− 0.62; P= 0.01). (c) Positive correlation between anterior cingulate glutamate+glutamine (Glx) and NAA levels in ﬁrst-episode
schizophrenia and controls (r= 0.80; P= 0.001). ●, First-episode schizophrenia; ○, controls.
Apoptosis and brain markers in schizophrenia
A Batalla et al
4
Translational Psychiatry (2015), 1 – 7
Glx and NAA levels were positively correlated in the AC (r= 0.80;
P= 0.001) of all participants (Figure 2). When data were analyzed
by group, the correlation was signiﬁcant in the FES group (r= 0.77;
P= 0.026) but not in controls (r= 0.84; P= 0.159).
Left thalamus. We found two negative correlations between Glx
and levels of caspase-3 activity (both baseline and 6 h after
treatment with STS 0.50 μM) that did not overcome the correction
for multiple comparisons (baseline r=− 0.59; P= 0.034; STS 0.5 μM
r=− 0.56; P= 0.047). No further correlations were found in the LT
between Glx or NAA levels and other apoptotic biomarkers.
Relationship between apoptotic markers and regional brain
volume
We did not ﬁnd signiﬁcant gray and white matter differences
between patients and controls. A negative correlation between
regional brain volume in the right superior temporal cortex and in
the postcentral gyrus and percentages of cells with CC after both
apoptosis inductions (STS 0.25 and 0.5 μM) was found (Po0.05
FWEc; Figure 3). The analysis by group could not be performed,
given that the sample size was lower than the degrees of freedom
needed. No other correlations between gray and white matter
volume and apoptotic biomarkers were found.
Relationship between metabolite levels and regional brain volume
None of the metabolites considered showed a signiﬁcant positive
or negative correlation with gray matter.
DISCUSSION
To the best of our knowledge, this is the ﬁrst neuroimaging study
to examine the relationship between brain metabolite levels and
regional brain volume and peripheral apoptotic biomarkers in
ﬁrst-episode antipsychotic-naive schizophrenia patients and con-
trols. Our results showed a negative correlation in the AC between
Glx and NAA levels and percentages of cells with CC in cultured
ﬁbroblasts obtained from skin biopsies. We further show that
regional brain volume in the right superior temporal cortex and in
the postcentral region was negatively correlated to the same
apoptotic biomarker. Taken together, these ﬁndings are consistent
with the neuroprogressive theories around the early stages of the
illness.
One of the deﬁning neuropathological features of schizophrenia
is GM loss in frontal and temporal regions, which is accelerated
during periadolescence.38 There has been substantial controversy
about what causes the progressive changes. Possible explanations
include the effects of medication,39 excitotoxicity induced by
N-methyl-D-aspartate Glu receptor dysfunction40 and reduced
neuropil,20 which may be inﬂuenced by local synaptic apoptosis.15
In our sample of untreated FES patients, we evaluated this
complex cell death mechanism by studying well-known hallmarks
of apoptosis such as the caspase-3 activity, the detection of
translocated phosphatidylserine and the identiﬁcation of cells
with fragmentation or CC. From direct analysis of apoptotic cells,
we previously reported higher apoptotic susceptibility in cultured
ﬁbroblasts from antipsychotic-naive ﬁrst-onset schizophrenia
patients compared with controls.15 In the present study we
further show that the mentioned apoptotic mechanisms are
related to brain markers, in particular with brain metabolites and
brain volume.
We did not ﬁnd differences in metabolite levels between FES
and controls in the AC or in the LT, which is in contrast with some
studies involving antipsychotic-naive FES and might be related to
our limited sample size. Such studies have usually found increased
Gln levels in both AC and thalamus in never-treated patients with
FES or subjects at high risk for psychosis,7,22–25 although lower7,26
and negative results have also been reported.27,28 Nevertheless,
we found a relationship between decreased glutamatergic and
NAA levels in the AC and increased cells with CC after both
apoptosis inductions with STS. This ﬁnding supports the notion of
an excitotoxic process, consistent with the idea that excitotoxicity
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Figure 3. Correlation of regional brain volume with chromatin condensation (CC) after apoptosis induction with staurosporine (STS) in ﬁrst-
episode schizophrenia (FES) and controls. (a) Signiﬁcant negative correlation in the right superior temporal and in the right postcentral after
apoptosis induction with STS 0.25 μM (Po0.001, family-wise error (FWE)-corrected at a cluster level). (b) Signiﬁcant negative correlation in the
right post-central region after apoptosis induction with STS 0.5 μM (Po0.001, FWE-corrected at a cluster level). Images are superimposed on
selected slices of a normalized brain and are oriented following the neurological convention (right= right). Voxels with Po0.001
(uncorrected) are displayed. Color bar represents t-value.
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occurs primarily in the early stages of the illness.19 It has been
proposed that levels of Glu and NAA would decrease over the
course of the illness, consistent with reports of decreased levels of
both Glu and Gln in the AC in patients with chronic
schizophrenia29,41,42 Aoyama et al.29 reported NAA and Glu
reductions between 10- and 80-month assessments in schizo-
phrenia patients, and both metabolites tended to be positively
correlated in the AC, which is consistent with our results. Decline
of NAA levels, which are thought to reﬂect neuronal integrity,
would be consistent with decreasing glutamatergic metabolite
levels, suggesting that both metabolites may reﬂect neuropil loss
or altered apoptosis. A recent meta-analysis by Marsman et al.43
provided additional support for a progressive decrease in frontal
Glu and Gln in patients with schizophrenia, possibly indicating a
progressive loss of synaptic activity. Although the results in the LT
did not overcome Bonferroni correction, the inverse relationship
between caspase-3 activity (both baseline and after apoptosis
induction with STS) and glutamatergic levels is also consistent
with the reported data in the AC. Caspase-3 is an important
apoptosis-inducing molecule acting in ﬁnal stages of this cell
death program,15 which has been suggested to increase
transiently around the onset of psychosis and later downregulate
as an appropriate long-term compensatory response to earlier
stress13 and may be due to second-generation antipsychotics,
which seem to be more neuroprotective than the ﬁrst generation
by upregulating antiapoptotic proteins.44,45
With regard to brain volume, there was no signiﬁcant difference
between FES and controls but the number of cells showing CC
after both apoptosis inductions with STS were negatively
correlated to the right superior temporal cortex and postcentral
areas in both groups. This suggests that cells that may experience
an increased apoptotic susceptibility may correlate with volu-
metric measures in these brain regions. This ﬁnding is also
consistent with studies showing loss of Glu and Gln related to GM
loss in subjects with schizophrenia or at high risk of developing
the disease.24,29 This approach may help to reﬂect speciﬁc
populations of neurons that may be more vulnerable to apoptosis
and contribute to the onset of schizophrenia.46 Several post-
mortem studies have examined spine density changes in brain
regions showing the greatest indices of GM loss in schizophrenia,
and these results support the view that spine density changes
directly contribute to GM loss in the disease.20,47 A reduction in
the superior temporal gyrus GM volume is one of the most
consistently reported alterations in the schizophrenia brain.48 At
the cellular level, patients with schizophrenia show a profound
reduction in spine density on pyramidal neurons in the superior
temporal gyrus.49 Gray matter volume covariance changes have
also been described in insula, amygdala and postcentral gyrus in
ﬁrst-episode treatment-naive schizophrenia patients.50 Although
post-mortem studies cannot identify the root cause of spine loss, it
is likely that spine formation and stability are reduced or spine
pruning is accelerated in schizophrenia.51,52
Although results involved patients and controls, it is important
to bear in mind that a greater percentage of cells undergoing
apoptosis was detected in samples from patients with FES
compared with controls.15 Therefore, in this study we have
revealed that peripheral apoptosis markers, which are increased in
FES patients, may correlate with brain markers, such as
metabolites and regional brain volume, providing further data
supporting neuroprogression in the early stages of schizophrenia.
Considering that the correlations were only present in the
schizophrenia group when the analysis was performed by group,
we postulate that such correlations are probably more pro-
nounced in these subjects compared with healthy controls.
However, the current sample size does not allow us to test
further this hypothesis.
Some potential limitations of the present study must be
discussed at this point. We acknowledge that the relatively small
number of subjects may have affected the sensitivity of our
measures and prevented the detection of differences in Glx and
NAA levels and regional brain volume between patients and
controls. Furthermore, it may have limited the detection of further
correlations between other apoptotic biomarkers and neuroimag-
ing brain markers. However, the strength of our observed
ﬁndings after appropriate corrections instills conﬁdence in their
validity. As we used a 3-Tesla scanner, we chose not to study Gln
and Glu metabolites separately, which hampers comparison
among studies. Studies reporting both metabolites have generally
employed 4-Tesla scanners.23,41 One signiﬁcant limitation of the
current approach is that the apoptotic proﬁle of peripheral
ﬁbroblasts does not necessarily reﬂect that of cortical brain tissue.
As we are relating a peripheral experimental model for
investigating apoptosis expected in neurons with central neuro-
imaging brain markers, results should be interpreted as exploratory
and need to be replicated. However, this complex and useful
model for studying neurodevelopmental and neurodegenerative
diseases53–55 provides valuable and novel data that highly
contribute to the understanding of the mechanisms that may
underlie neuroprogression in schizophrenia. In addition, the
longitudinal 1H-MRS data and biopsies that we are collecting in
this sample will help to clarify whether the observed relationships
between apoptotic peripheral and brain neuroimaging markers
change over time.
Overall, the present results expand our previous data of
increased apoptosis susceptibility in ﬁrst-episode antipsychotic-
naive schizophrenia patients compared with controls revealing for
the ﬁrst time that peripheral markers of apoptosis obtained in
cultured ﬁbroblasts may correlate with brain metabolites, Glx and
NAA, and regional brain volume, which is consistent with
neuroprogression in the early stages of schizophrenia.
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